LS
LCTX icon

Lupo Securities’s Lineage Cell Therapeutics LCTX Stock Holding History

Lupo Securities’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,472
Closed -$4.43K – 574
2014
Q4 		$4.43K Buy
+1,472
New +$3.98K ﹤0.01% 405

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lupo Securities's LCTX Position: Q1 2015 in Review

Lupo Securities sold out of Lineage Cell Therapeutics (LCTX) in Q1 2015, closing a stake of 1,472 shares — an estimated $4.43K sold.

Lupo Securities first reported a position in LCTX in Q4 2014 and held it in 1 quarter. The position peaked at $4.43K in Q4 2014. 69 funds tracked by Wall St. Rank hold LCTX as of Q1 2015.

  • Lupo Securities reported no remaining Lineage Cell Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Lupo Securities sold 1,472 Lineage Cell Therapeutics shares in Q1 2015, an estimated $4.43K.
  • Lupo Securities first reported a position in Lineage Cell Therapeutics in Q4 2014 and held it in 1 quarter.
  • Lupo Securities's Lineage Cell Therapeutics position peaked at $4.43K in Q4 2014.
  • 69 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2015.

Based on Lupo Securities's 13F filing for Q1 2015, filed 15 May 2015.